the fragility of product/market is shown each week in the never ending race as AI models improve improve improve newer models make prior ones obsolete, showing that PMF isn’t just about your product’s features, but how it compares to alternatives across the ecosystem Product/market fit follows the frontier. What was perfectly good and powerful one week is ignored the next. I know that a few months ago I thought Opus 4.5 was amazing. Today I can’t imagine using it when Opus 5 is available Thus your moat depends on your ability to deliver the next innovation, then the next after that…

With two months until the US midterm elections, the options market is showing a mix of fragility and ​fearlessness, with some analysts worried markets are ill-prepared to absorb any shock

8/8 — WHEN LIFESTYLE ISN'T ENOUGH For established osteoporosis, recent fragility fracture, T-score at or below −3.0, or multiple risk factors — lifestyle is the foundation, not the whole answer. Escalate without apology. Denosumab (Prolia) — potent anti-resorptive, every six months, strong fracture reduction at spine and hip. Never stop abruptly without transitioning to another agent. Teriparatide (Forteo) — anabolic, actually builds new bone. Daily injection, typically limited to two years, then follow with an anti-resorptive to lock in the gains. Romosozumab (Evenity) — dual action. Monthly for 12 months, then transition. Note the cardiovascular boxed warning — screen carefully. Sequence matters enormously: in very high-risk patients, starting with an anabolic and then following with an anti-resorptive produces larger density gains than the reverse order. Here's where I've landed after twenty years. I no longer treat bone as secondary. Independence in your final decades is not a lifestyle preference — it's everything. Bone is not destiny. It is living tissue that responds to the signals you send it. Send it better ones. Starting this week.